BioFire Warrior Panel Control Kit
BioFire Defense, LLC · Decision date Nov 4, 2026
What did the FDA decide?
The FDA's 510(k) record K262842 covers the BioFire Warrior Panel Control Kit, submitted by BioFire Defense, LLC of Salt Lake City, Utah, with David Rabiger listed as applicant contact. The record places the submission under regulation number 866.392023 and the Microbiology specialty, with product code PMN. The listed receipt date is 08/12/2026.
The recorded decision is SESE, dated 2026-11-04. In 510(k) terms this denotes a substantially equivalent determination, meaning the control kit may be marketed on that basis; it is not a premarket approval of a new device. The record does not describe the kit's contents, its intended use, the predicate device, or any performance data, so those details remain unknown from this source.
The public record also does not state whether the submission was a traditional or abbreviated 510(k), nor does it identify any cleared device the kit is used with. Readers should treat the decision as a clearance determination for the named control kit only.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Microbiology
- Decision date
- Nov 4, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K262842
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- BioFire Defense, LLC
- Product code
- PMN
- Decision code
- SESE
- Decision date
- Nov 4, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Assayed External Control Material For Microbiology Nucleic Acid Amplification (Nat) Assays.
- Applicant
- BioFire Defense, LLC
- Product code
- PMN
- FDA device class
- 2
FDA decision timeline
K262842 received
Application receipt date recorded by FDA.
K262842 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code PMN
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Maine Molecular Quality Controls, Inc. | 510(k) clearance | Oct 30, 2026 | FDA | |
| Maine Molecular Quality Controls, Inc. | 510(k) clearance | Oct 21, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
BioFire Defense, LLC
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Salt Lake City, UT
Sources and methodology
- Original FDA record: K262842
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
